Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDREP spermatogenesis study in men with sickle cell disease
2009-017940-15Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydroxyurea in sickle cell disease (SCD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in sperm count after 6 months. Started Feb 2010; status: active.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2009-017940-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017940-15.